Anika Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $29,612 | $30,615 | $27,817 | $28,219 |
Gross Profit | 18,997 | 19,179 | 15,584 | 14,363 |
EBITDA | -4,081 | 1,964 | -1,833 | -2,679 |
EBIT | -5,488 | 646 | -3,233 | -4,179 |
Net Income | -5,056 | 292 | -2,329 | -3,970 |
Net Change In Cash | 29,612 | 30,615 | 27,817 | 28,219 |
Free Cash Flow | -6,277 | 3,989 | 4,983 | -1,656 |
Cash | 41,020 | 57,481 | 57,990 | 53,167 |
Basic Shares | 13,531 | 14,669 | 14,419 | 14,364 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $112,819 | $119,907 | $120,792 | $156,236 |
Gross Profit | 63,807 | 75,998 | 82,532 | 93,576 |
EBITDA | -5,322 | 3,020 | 15,061 | -4,913 |
EBIT | -11,051 | -5,101 | 844 | -19,400 |
Net Income | -10,880 | -56,385 | -82,667 | -14,859 |
Net Change In Cash | 112,819 | 119,907 | 120,792 | 156,236 |
Cost of Revenue | -7,929 | |||
Free Cash Flow | 4,362 | -2,331 | -7,215 | -3,077 |
Cash | 57,481 | 55,629 | 68,740 | 86,327 |
Basic Shares | 14,339 | 14,721 | 14,656 | 14,561 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.37 |
2025-12-31 | $0.31 |
2025-09-30 | $0.04 |
2025-06-30 | -$0.13 |